Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

7Total
P 1 (4)
P 2 (3)

Trial Status

Recruiting4
Active Not Recruiting1
Enrolling By Invitation1
Unknown1

Clinical Trials (7)

Showing 7 of 7 trials
NCT04771572Phase 1Recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT05828589Phase 1Active Not Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

NCT07168486Phase 1Enrolling By Invitation

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

NCT05107674Phase 1Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

NCT04792489Phase 2Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

NCT04271956Phase 2RecruitingPrimary

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation

NCT04992377Phase 2UnknownPrimary

R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL

Showing all 7 trials

Research Network

Activity Timeline